Comparative Pharmacology
Head-to-head clinical analysis: DYNAPEN versus PENTIDS 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNAPEN versus PENTIDS 400.
DYNAPEN vs PENTIDS '400'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dynapen (dicloxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours for skin and soft tissue infections; up to 500 mg every 6 hours for respiratory tract infections.
400 mg orally every 6 hours.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria.
0.5-1 hour in patients with normal renal function. Prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <10%.
Primarily renal (tubular secretion and glomerular filtration); 60-90% of dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<10%) and fecal elimination.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic